Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer

Figure 4

Reduced CDCP1 expression reduces avidity of CDCP1-targing antibody 10D7 for patient-derived model CRC13 in mice. (a) Representative image of H&E stained (bottom) and anti-CDCP1 immunohistochemical staining (top) of subcutaneous CRC13-shScr (left) and CRC13-shCDCP1 (right) xenografts in mice. Anti-CDCP1 immunohistochemistry demonstrated markedly reduced expression of CDCP1 in CRC13-shCDCP1 tumors compared with CRC13-shScr tumors. H&E staining indicated that histology of xenografts was unaltered by reduced levels of CDCP1 (scale bar 50 μm). (b) Representative 3D PET-CT reconstructions of mice bearing CRC13-shScr (red circle) and CRC13-shCDCP1 (blue circle) tumors at 1, 24, 48, 72, and 144 hours after ⁸⁹Zr-10D7 administration (1MBq). (c) In vivo PET avidity of tumors at time points following ⁸⁹Zr-10D7 administration displayed as %ID/cc. (d) Quantitative ex vivo biodistribution data determined by radiometric analysis of excised tumors at the end of the assay. , ; , ; , .

(a)

(b)

(c)

(d)